Positrigo's Portable Brain PET System Receives FDA Clearance
The FDA has granted clearance to Positrigo's NeuroLF Brain PET system, a portable device for diagnosing multiple brain disorders. The technology is designed to bring specialized neuroimaging into outpatient and potentially mobile environments. This clearance represents a notable advance in making sophisticated diagnostic tools more accessible outside of large hospital settings.
- The clearance of Positrigo's NeuroLF system is timely, aligning with the recent FDA approval of new Alzheimer's disease therapies that are expected to increase demand for brain PET scans. This trend is significant as Alzheimer's accounts for approximately 70% of all dementias in individuals over 60. - Positrigo, a 2018 spin-off from ETH Zurich, has raised over $18.2 million in funding to bring its ultra-compact brain PET scanner to market. The company is now scaling up production to meet existing pre-orders in the U.S. and is also pursuing regulatory approval in Europe. - The broader U.S. imaging market is seeing a significant shift in volume from hospital settings to outpatient centers, which now account for about 40% of all radiology procedures. This is driven by the need for more convenient and cost-effective care, prompting health systems to invest in smaller-footprint equipment suitable for clinics or mobile units. - The global mobile imaging services market was valued at USD 2.09 billion in 2024 and is projected to grow, driven by an aging population and the rising prevalence of chronic diseases. In the U.S., hospital outpatient departments (HOPDs) are expected to be the fastest-growing segment for diagnostic imaging services. - For mobile PET/CT services specifically, technological advancements like AI-assisted consoles, faster rotation speeds, and time-of-flight imaging are improving efficiency and image quality. These mobile units provide immediate capacity for health systems, helping to manage patient backlogs and maintain services during equipment upgrades. - Recent Medicare reimbursement changes are impacting the financial landscape for imaging services. While the 2025 Medicare Physician Fee Schedule includes an overall reduction, CMS has increased payment rates for certain procedures and will now separately reimburse for high-cost diagnostic radiopharmaceuticals in the hospital outpatient setting. - Competition in the mobile imaging market is characterized by both established players like Siemens Healthineers and GE Healthcare and emerging companies. Strategic initiatives include partnerships with healthcare providers and acquisitions to expand service offerings and regional presence. - From a regulatory and best-practices standpoint, the American College of Radiology (ACR) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have established credentialing guidelines for physicians interpreting brain PET scans to ensure competency. These standards are crucial as new technologies like the NeuroLF become more widespread.
